An increase in Cdc42 activity in melphalan/bortezomib-resistant cells also indicates that enhanced Cdc42 activity may be used as a biomarker to identify melphalan/bortezomib-resistant MM patients who are most likely to benefit from CASIN treatment. Here, CDC42 is linked to Miyoshi myopathy.